INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease

Stock Information for INmune Bio Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About INmune Bio Inc.

INmune Bio Receives Favorable Patentability Opinion for CORDStrom(TM) Platform Technology
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom(TM) Manufacturing for Commercial Readiness
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
INmune Bio Opens Phase II in High Dose Cohort of INKmune(TM) Trial in Prostate Cancer
INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
INmune Bio Inc. Expands INKmune Trial in Prostate Cancer to Veterans

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.